Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, efficacy, and pharmacokinetics of VPRIV in Chinese subjects with type 1 Gaucher disease
2022-002323-35Phase 3
- Sponsor
- Takeda
- Start
- Nov 2022
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of velaglucerase alfa in Gaucher disease type 1 (GD1), sponsored by Takeda. Primary endpoint: Serious treatment-emergent adverse events.
02
Drugs
velaglucerase alfa
03
Conditions
Gaucher disease type 1 (GD1)
Beyond the preview
Go deeper on 2022-002323-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002323-35.